Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
试验速览
- 阶段
- 不适用
- 入组人数
- 10,000
- 试验地点
- 1
- 主要终点
- Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate
研究概览
简要总结
The objective of this study was to investigate the current situation of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use. Further, the investigators assessed the outcomes of patients who developed VA-AKI and the risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for improving the prevention and treatment of VA-AKI in China.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Using Vancomycin
- •≥18 years old
排除标准
- •Medical records were incomplete
- •Had been diagnosed with stage 5 CKD or were regularly receiving dialysis
- •SCr were not being adequately monitored to detect the development of AKI
- •Had undergone nephrectomy
研究组 & 干预措施
VAN-AKI
Patients who had vancomycin associated acute kidney injury.
干预措施: Vancomycin (Drug)
结局指标
主要结局
Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate
时间窗: 1 year
次要结局
- VAN-AKI detection rate(1 year)
- TDM detction rate(1 year)
- 0h Serum creatinine detction rate(1 year)
- 48h Serum creatinine detction rate(1 year)
研究者
Cui Yimin
Chief pharmacist
Peking University First Hospital
